Change of executive director and change in composition of nomination committee
Filed with HKEX · Stock code 2656 · · 3 pages · English
Summary by 6ix AI
This filing reports a change in executive director and the composition of the nomination committee at 160 Health International Ltd. Mr. Wang Lifa has resigned as an executive director to focus on personal commitments, effective from a future date. Ms. Wu Shixuan has been appointed as an executive director and a member of the nomination committee, also effective from the same future date. The changes ensure compliance with gender diversity requirements in the nomination committee.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
160 Health International Ltd. on 6ix
Earlier from 160 Health International
- Voluntary announcement business progress under the strategic cooperation framework agreement
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended September 30, 2026
- Inside information signing of strategic cooperation framework agreement
- Reminder letter and reply form to non-registered holders - reminder letter regarding the arrangement of electronic dissemination of corporate communications
- Reminder letter and reply form to registered shareholders - reminder letter regarding the arrangement of electronic dissemination of corporate communications
Later from 160 Health International
- List of directors and their roles and functions
- Proposed change of auditor
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended October 31, 2026
Follow 160 Health International into a list and get an email when it puts out news.
Follow 160 Health International